This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Best, C. J.M. Articles by Chuaqui, R. F. Search for Related Content PubMed PubMed Citation Articles by Best, C. J.M. Articles by Chuaqui, R. F.

Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy

Authors' Affiliations: ¹ Pathogenetics Unit, Laboratory of Pathology; ² Laboratory of Pathology; ³ Urologic Oncology Branch; and ⁴ Molecular Pharmacology Section, Cancer Therapeutics Branch, National Cancer Institute, NIH, Bethesda, Maryland; ⁵ Science Applications International Corporation-Frederick, Inc., National Cancer Institute at Frederick, Frederick, Maryland; ⁶ Division Genetic Medicine, Department of Medicine and ⁷ Department of Urologic Surgery, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; ⁸ Advanced Technology Center, National Cancer Institute, Gaithersburg, Maryland; and Departments of ⁹ Pathology and ¹⁰ Urology, Catholic University, Santiago, Chile

Requests for reprints: Carolyn J.M. Best, Pathogenetics Unit, Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD 20892. Phone: 301-451-8544; Fax: 301-402-8910; E-mail: bestcar{at}mail.nih.gov.

Purpose: After an initial response to androgen ablation, most prostate tumors recur, ultimately progressing to highly aggressive androgen-independent cancer. The molecular mechanisms underlying progression are not well known in part due to the rarity of androgen-independent samples from primary and metastatic sites.

Experimental Design: We compared the gene expression profiles of 10 androgen-independent primary prostate tumor biopsies with 10 primary, untreated androgen-dependent tumors. Samples were laser capture microdissected, the RNA was amplified, and gene expression was assessed using Affymetrix Human Genome U133A GeneChip. Differential expression was examined with principal component analysis, hierarchical clustering, and Student's t testing. Analysis of gene ontology was done with Expression Analysis Systematic Explorer and gene expression data were integrated with genomic alterations with Differential Gene Locus Mapping.

Results: Unsupervised principal component analysis showed that the androgen-dependent and androgen-independent tumors segregated from one another. After filtering the data, 239 differentially expressed genes were identified. Two main gene ontologies were found discordant between androgen-independent and androgen-dependent tumors: macromolecule biosynthesis was down-regulated and cell adhesion was up-regulated in androgen-independent tumors. Other differentially expressed genes were related to interleukin-6 signaling as well as angiogenesis, cell adhesion, apoptosis, oxidative stress, and hormone response. The Differential Gene Locus Mapping analysis identified nine regions of potential chromosomal deletion in the androgen-independent tumors, including 1p36, 3p21, 6p21, 8p21, 11p15, 11q12, 12q23, 16q12, and 16q21.

Conclusions: Taken together, these data identify several unique characteristics of androgen-independent prostate cancer that may hold potential for the development of targeted therapeutic intervention.

This article has been cited by other articles:

				P. Mendiratta, E. Mostaghel, J. Guinney, A. K. Tewari, A. Porrello, W. T. Barry, P. S. Nelson, and P. G. Febbo Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer J. Clin. Oncol., April 20, 2009; 27(12): 2022 - 2029. [Abstract] [Full Text] [PDF]

				G. Wang, S. Haile, B. Comuzzi, A. H. Tien, J. Wang, T. M.K. Yong, A. E. Jelescu-Bodos, N. Blaszczyk, R. L. Vessella, B. A. Masri, et al. Osteoblast-Derived Factors Induce an Expression Signature that Identifies Prostate Cancer Metastasis and Hormonal Progression Cancer Res., April 15, 2009; 69(8): 3433 - 3442. [Abstract] [Full Text] [PDF]

				Z. Guo, X. Yang, F. Sun, R. Jiang, D. E. Linn, H. Chen, H. Chen, X. Kong, J. Melamed, C. G. Tepper, et al. A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth Cancer Res., March 15, 2009; 69(6): 2305 - 2313. [Abstract] [Full Text] [PDF]

				N. Sharifi Commentary: Antioxidants for Cancer: New Tricks for an Old Dog? Oncologist, March 1, 2009; 14(3): 213 - 215. [Abstract] [Full Text] [PDF]

				G. Wang, J. Wang, and M. D. Sadar Crosstalk between the Androgen Receptor and {beta}-Catenin in Castrate-Resistant Prostate Cancer Cancer Res., December 1, 2008; 68(23): 9918 - 9927. [Abstract] [Full Text] [PDF]

				G. Castellano, G. Malaponte, M. C. Mazzarino, M. Figini, F. Marchese, P. Gangemi, S. Travali, F. Stivala, S. Canevari, and M. Libra Activation of the Osteopontin/Matrix Metalloproteinase-9 Pathway Correlates with Prostate Cancer Progression Clin. Cancer Res., November 15, 2008; 14(22): 7470 - 7480. [Abstract] [Full Text] [PDF]

				N. Sharifi, E. M. Hurt, S. B. Thomas, and W. L. Farrar Effects of Manganese Superoxide Dismutase Silencing on Androgen Receptor Function and Gene Regulation: Implications for Castration-Resistant Prostate Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6073 - 6080. [Abstract] [Full Text] [PDF]

				R. J. Jin, Y. Lho, L. Connelly, Y. Wang, X. Yu, L. Saint Jean, T. C. Case, K. Ellwood-Yen, C. L. Sawyers, N. A. Bhowmick, et al. The Nuclear Factor-{kappa}B Pathway Controls the Progression of Prostate Cancer to Androgen-Independent Growth Cancer Res., August 15, 2008; 68(16): 6762 - 6769. [Abstract] [Full Text] [PDF]

				F. Kosari, J. M. A. Munz, C. D. Savci-Heijink, C. Spiro, E. W. Klee, D. M. Kube, L. Tillmans, J. Slezak, R. J. Karnes, J. C. Cheville, et al. Identification of Prognostic Biomarkers for Prostate Cancer Clin. Cancer Res., March 15, 2008; 14(6): 1734 - 1743. [Abstract] [Full Text] [PDF]

				J. Domingo-Domenech, C. Oliva, A. Rovira, J. Codony-Servat, M. Bosch, X. Filella, C. Montagut, M. Tapia, C. Campas, L. Dang, et al. Interleukin 6, a Nuclear Factor-{kappa}B Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-{kappa}B Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity. Clin. Cancer Res., September 15, 2006; 12(18): 5578 - 5586. [Abstract] [Full Text] [PDF]

				M. Stanbrough, G. J. Bubley, K. Ross, T. R. Golub, M. A. Rubin, T. M. Penning, P. G. Febbo, and S. P. Balk Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res., March 1, 2006; 66(5): 2815 - 2825. [Abstract] [Full Text] [PDF]